The antiserum was produced against synthesized peptide derived from human MEK1 around the phosphorylation site of Ser298. AA range:264-313

Phospho-MEK1 (S298) Polyclonal Antibody detects endogenous levels of MEK1 protein only when phosphorylated at S298.The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):PLsSY

MAP2K1

Dual specificity mitogen-activated protein kinase kinase 1

MAP2K1 ;
MEK1 ;
PRKMK1 ;
Dual specificity mitogen-activated protein kinase kinase 1 ;
MAP kinase kinase 1 ;
MAPKK 1 ;
MKK1 ;
ERK activator kinase 1 ;
MAPK/ERK kinase 1 ;
MEK 1

The protein encoded by this gene is a member of the dual specificity protein kinase family , which acts as a mitogen-activated protein (MAP) kinase kinase. MAP kinases , also known as extracellular signal-regulated kinases (ERKs) , act as an integration point for multiple biochemical signals. This protein kinase lies upstream of MAP kinases and stimulates the enzymatic activity of MAP kinases upon wide variety of extra- and intracellular signals. As an essential component of MAP kinase signal transduction pathway , this kinase is involved in many cellular processes such as proliferation , differentiation , transcription regulation and development. [provided by RefSeq , Jul 2008] ,

Catalytic activity:ATP + a protein = ADP + a phosphoprotein. ,Disease:Defects in MAP2K1 are a cause of cardiofaciocutaneous syndrome (CFC syndrome) [MIM:115150]; also known as cardio-facio-cutaneous syndrome. CFC syndrome is characterized by a distinctive facial appearance , heart defects and mental retardation. Heart defects include pulmonic stenosis , atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse , friable hair , hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction , hypoplastic supraorbital ridges , downslanting palpebral fissures , a depressed nasal bridge , and posteriorly angulated ears with prominent helices. The inheritance of CFC syndrome is autosomal dominant. ,enzyme regulation:Activated by phosphorylation. ,Function:Catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. Activates ERK1 and ERK2 MAP kinases. ,PTM:Acetylation by Yersinia yopJ prevents phosphorylation and activation , thus blocking the MAPK signaling pathway. ,PTM:Phosphorylation on Ser/Thr by MAP kinase kinase kinases (RAF or MEKK1) regulates positively the kinase activity. ,similarity:Belongs to the protein kinase superfamily. ,similarity:Belongs to the protein kinase superfamily. STE Ser/Thr protein kinase family. MAP kinase kinase subfamily. ,similarity:Contains 1 protein kinase domain. ,subunit:Interacts with MORG1 (By similarity) . Interacts with Yersinia yopJ. ,

Cytoplasm , cytoskeleton , microtubule organizing center , centrosome . Cytoplasm , cytoskeleton , microtubule organizing center , spindle pole body . Cytoplasm . Nucleus . Membrane ; Peripheral membrane protein . Localizes at centrosomes during prometaphase , midzone during anaphase and midbody during telophase/cytokinesis (PubMed:14737111) . Membrane localization is probably regulated by its interaction with KSR1 (PubMed:10409742) . .

>>EGFR tyrosine kinase inhibitor resistance ;
>>Endocrine resistance ;
>>MAPK signaling pathway ;
>>ErbB signaling pathway ;
>>Ras signaling pathway ;
>>Rap1 signaling pathway ;
>>cGMP-PKG signaling pathway ;
>>cAMP signaling pathway ;
>>Chemokine signaling pathway ;
>>HIF-1 signaling pathway ;
>>FoxO signaling pathway ;
>>Sphingolipid signaling pathway ;
>>Phospholipase D signaling pathway ;
>>Oocyte meiosis ;
>>Autophagy - animal ;
>>mTOR signaling pathway ;
>>PI3K-Akt signaling pathway ;
>>Apoptosis ;
>>Cellular senescence ;
>>Vascular smooth muscle contraction ;
>>VEGF signaling pathway ;
>>Apelin signaling pathway ;
>>Osteoclast differentiation ;
>>Focal adhesion ;
>>Gap junction ;
>>Signaling pathways regulating pluripotency of stem cells ;
>>Neutrophil extracellular trap formation ;
>>Toll-like receptor signaling pathway ;
>>Natural killer cell mediated cytotoxicity ;
>>T cell receptor signaling pathway ;
>>B cell receptor signaling pathway ;
>>Fc epsilon RI signaling pathway ;
>>Fc gamma R-mediated phagocytosis ;
>>TNF signaling pathway ;
>>Long-term potentiation ;
>>Neurotrophin signaling pathway ;
>>Cholinergic synapse ;
>>Serotonergic synapse ;
>>Long-term depression ;
>>Regulation of actin cytoskeleton ;
>>Insulin signaling pathway ;
>>GnRH signaling pathway ;
>>Progesterone-mediated oocyte maturation ;
>>Estrogen signaling pathway ;
>>Melanogenesis ;
>>Prolactin signaling pathway ;
>>Thyroid hormone signaling pathway ;
>>Oxytocin signaling pathway ;
>>Relaxin signaling pathway ;
>>Parathyroid hormone synthesis , secretion and action ;
>>GnRH secretion ;
>>Cushing syndrome ;
>>Growth hormone synthesis , secretion and action ;
>>Alzheimer disease ;
>>Pathways of neurodegeneration - multiple diseases ;
>>Alcoholism ;
>>Salmonella infection ;
>>Yersinia infection ;
>>Hepatitis C ;
>>Hepatitis B ;
>>Human cytomegalovirus infection ;
>>Influenza A ;
>>Human papillomavirus infection ;
>>Human T-cell leukemia virus 1 infection ;
>>Kaposi sarcoma-associated herpesvirus infection ;
>>Human immunodeficiency virus 1 infection ;
>>Pathways in cancer ;
>>Proteoglycans in cancer ;
>>MicroRNAs in cancer ;
>>Chemical carcinogenesis - receptor activation ;
>>Chemical carcinogenesis - reactive oxygen species ;
>>Colorectal cancer ;
>>Renal cell carcinoma ;
>>Pancreatic cancer ;
>>Endometrial cancer ;
>>Glioma ;
>>Prostate cancer ;
>>Thyroid cancer ;
>>Melanoma ;
>>Bladder cancer ;
>>Chronic myeloid leukemia ;
>>Acute myeloid leukemia ;
>>Non-small cell lung cancer ;
>>Breast cancer ;
>>Hepatocellular carcinoma ;
>>Gastric cancer ;
>>Central carbon metabolism in cancer ;
>>Choline metabolism in cancer ;
>>PD-L1 expression and PD-1 checkpoint pathway in cancer